Aktis Oncology Q2 net loss widens on higher R&D, administrative costs
AKTS•Outlook
- Company expects to initiate Phase 1b trial of AKY-2519 in B7-H3 solid tumors in H2 2026
- Aktis expects preliminary data from Phase 1b NECTINIUM-2 trial of AKY-1189 in Q1 2027
- Company's in-house GMP facility expected to be operational in H2 2026 to support clinical supply
Overview
- US oncology drug developer's Q2 collaboration revenue rose yr/yr on Eli Lilly partnership progress
- Operating expenses and net loss increased due to higher R&D and administrative costs
- Company ended Q2 with $517 mln in cash, expects to fund operations into 2029
Result Drivers
- Lilly collaboration - Collaboration revenue rose due to continued advancement of research partnership with Eli Lilly
- Clinical trial spending - Higher R&D expenses driven by ongoing Phase 1b trials for AKY-1189 and initiation of clinical trials for AKY-2519
- Administrative costs - General and administrative expenses rose due to increased hiring and public company operating costs
Key details and analyst coverage
Related News
Phillips 66 EVP Refining Richard G. Harbison disposes of 52,100 common shares worth $11.66 million
PSX•
U.S. FDA Grants Accelerated Approval To Bristol Myers Squibb's First Celmod Therapy Zenbexus™, In Combination With Daratumumab And Hyaluronidase-Fihj And Dexamethasone (Zdd) For Patients With Multiple Myeloma, As Early As First Relapse
BMY•
